NASDAQ:ARRY - Array Biopharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$25.60 -0.17 (-0.66 %)
(As of 05/22/2019 10:31 AM ET)
Previous Close$25.77
Today's Range$25.41 - $26.13
52-Week Range$12.56 - $26.82
Volume38,355 shs
Average Volume3.24 million shs
Market Capitalization$5.68 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.4
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer and other diseases in North America, Europe, and the Asia Pacific. It provides BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF mutation. The company's lead clinical programs include encorafenib and binimetinib that are investigated in approximately 30 clinical trials for various solid tumor indications, including a Phase III trial in BRAF-mutant colorectal cancer. Its product pipeline also includes ipatasertib, an AKT inhibitor that is in Phase III trial to treat prostate or breast cancers; selumetinib, a MEK inhibitor for cancer; larotrectinib, a PanTrk inhibitor that is in a Phase II/registration clinical trial for cancer; tucatinib, a HER2 inhibitor for breast cancer, which is in Phase II/registration trial; and ARRY-797 that is in Phase III clinical trial for Lamin A/C-related dilated cardiomyopathy. In addition, the company is developing varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric cancer; ARRY-382, a CSF1R inhibitor that is in Phase II clinical trial to treat cancer; motolimod/VTX-2337, a Toll-like receptor that is in Phase II clinical trial for cancer; and prexasertib/LY2606368, a CHK-1 inhibitor, which is in multiple Phase I or II clinical trials for cancer. Further, its drug candidates in Phase I clinical trials include GDC-0575, a CHK-1 inhibitor for cancer; LOXO-292, a RET inhibitor to treat cancer; and LOXO-195, a Trk inhibitor for cancer. Additionally, its drug candidates include Ganovo/danoprevir, a protease inhibitor for hepatitis C virus. The company was founded in 1998 and is headquartered in Boulder, Colorado.

Receive ARRY News and Ratings via Email

Sign-up to receive the latest news and ratings for ARRY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ARRY
CUSIP04269X10
Phone303-381-6600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$173.77 million
Book Value$1.36 per share

Profitability

Net Income$-147,340,000.00

Miscellaneous

Employees298
Market Cap$5.68 billion
Next Earnings Date8/13/2019 (Estimated)
OptionableOptionable

Array Biopharma (NASDAQ:ARRY) Frequently Asked Questions

What is Array Biopharma's stock symbol?

Array Biopharma trades on the NASDAQ under the ticker symbol "ARRY."

How were Array Biopharma's earnings last quarter?

Array Biopharma Inc (NASDAQ:ARRY) released its quarterly earnings results on Tuesday, May, 7th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.21) by $0.04. The biopharmaceutical company had revenue of $64.68 million for the quarter, compared to analysts' expectations of $54.04 million. Array Biopharma had a negative net margin of 52.64% and a negative return on equity of 48.51%. Array Biopharma's revenue was down 2.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.11) earnings per share. View Array Biopharma's Earnings History.

When is Array Biopharma's next earnings date?

Array Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for Array Biopharma.

What price target have analysts set for ARRY?

10 brokerages have issued twelve-month price targets for Array Biopharma's stock. Their forecasts range from $20.00 to $35.00. On average, they anticipate Array Biopharma's share price to reach $29.1111 in the next twelve months. This suggests a possible upside of 13.9% from the stock's current price. View Analyst Price Targets for Array Biopharma.

What is the consensus analysts' recommendation for Array Biopharma?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Array Biopharma in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Array Biopharma.

Has Array Biopharma been receiving favorable news coverage?

Media stories about ARRY stock have trended somewhat positive on Wednesday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Array Biopharma earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days.

Are investors shorting Array Biopharma?

Array Biopharma saw a increase in short interest in the month of April. As of April 30th, there was short interest totalling 23,968,031 shares, an increase of 0.8% from the April 15th total of 24,158,679 shares. Based on an average daily trading volume, of 2,015,645 shares, the short-interest ratio is currently 11.9 days. Approximately 11.1% of the company's shares are sold short. View Array Biopharma's Current Options Chain.

Who are some of Array Biopharma's key competitors?

What other stocks do shareholders of Array Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Array Biopharma investors own include Puma Biotechnology (PBYI), Medivation (Mdvn), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), Exelixis (EXEL), United Continental (UAL), Kite Pharma (KITE) and Synergy Pharmaceuticals (SGYP).

Who are Array Biopharma's key executives?

Array Biopharma's management team includes the folowing people:
  • Mr. Ron Squarer, CEO & Director (Age 52)
  • Mr. Jason Haddock, Chief Financial Officer (Age 49)
  • Mr. Andrew R. Robbins, Chief Operating Officer (Age 43)
  • Dr. Victor Sandor, Chief Medical Officer (Age 53)
  • Dr. Nicholas A. Saccomano, Chief Scientific Officer (Age 60)

Who are Array Biopharma's major shareholders?

Array Biopharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.80%), Perceptive Advisors LLC (1.91%), BVF Inc. IL (1.54%), Morgan Stanley (1.52%), Geode Capital Management LLC (1.24%) and Northern Trust Corp (1.20%). Company insiders that own Array Biopharma stock include Andrew R Robbins, Carrie Smith Cox, Charles M Baum, Curtis Gale Oltmans, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Nicholas A Saccomano, Ron Squarer and Victor Sandor. View Institutional Ownership Trends for Array Biopharma.

Which major investors are selling Array Biopharma stock?

ARRY stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., BVF Inc. IL, Handelsbanken Fonder AB, Voya Investment Management LLC, Neuberger Berman Group LLC, Columbus Circle Investors, Apis Capital Advisors LLC and Peregrine Capital Management LLC. Company insiders that have sold Array Biopharma company stock in the last year include Andrew R Robbins, Curtis Gale Oltmans, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Nicholas A Saccomano, Ron Squarer and Victor Sandor. View Insider Buying and Selling for Array Biopharma.

Which major investors are buying Array Biopharma stock?

ARRY stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Marshall Wace North America L.P., Macquarie Group Ltd., Gilder Gagnon Howe & Co. LLC, Morgan Stanley, Wellington Management Group LLP, Federated Investors Inc. PA and Fiera Capital Corp. View Insider Buying and Selling for Array Biopharma.

How do I buy shares of Array Biopharma?

Shares of ARRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Array Biopharma's stock price today?

One share of ARRY stock can currently be purchased for approximately $25.56.

How big of a company is Array Biopharma?

Array Biopharma has a market capitalization of $5.67 billion and generates $173.77 million in revenue each year. The biopharmaceutical company earns $-147,340,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. Array Biopharma employs 298 workers across the globe.

What is Array Biopharma's official website?

The official website for Array Biopharma is http://www.arraybiopharma.com/.

How can I contact Array Biopharma?

Array Biopharma's mailing address is 3200 Walnut Street, Boulder CO, 80301. The biopharmaceutical company can be reached via phone at 303-381-6600 or via email at [email protected]


MarketBeat Community Rating for Array Biopharma (NASDAQ ARRY)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  450 (Vote Outperform)
Underperform Votes:  269 (Vote Underperform)
Total Votes:  719
MarketBeat's community ratings are surveys of what our community members think about Array Biopharma and other stocks. Vote "Outperform" if you believe ARRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/22/2019 by MarketBeat.com Staff

Featured Article: Current Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel